FUJIREBIO-EUROPE
23.6.2022 09:41:07 CEST | Business Wire | Press release
H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending the satisfaction of customary closing conditions, the deal is expected to close in July 2022. ADx NeuroSciences becomes a wholly owned subsidiary of Fujirebio Europe NV.
“ By welcoming ADx NeuroSciences in the Fujirebio group of companies, Fujirebio will be able to expand its antibody supply business and contract development and manufacturing (CDMO) offerings in the neurodegenerative field to our partners globally,” says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “Fujirebio is committed to invest in developing diagnostic kits in the field of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. We are excited to work together with the ADx NeuroSciences team to expand the global neurodegeneration biomarker testing market.”
“It is a unique opportunity for us to completely integrate the CDMO-based open platform strategy of Fujirebio in this way,” states Koen Dewaele, CEO of ADx NeuroSciences. “Our partners will benefit from the synergies between our teams and the speed with which we can bring our antibodies and assays to the diagnostics industry and on various platforms, all under the high-quality mark of excellence for which Fujirebio has become well known.”
ADx NeuroSciences specializes in generating tailor-made antibodies and developing assays for pharma and in vitro diagnostics (IVD) companies. As part of Fujirebio, ADx NeuroSciences will continue to serve its current partners and customers in their diagnostic biomarker development and will continue to expand its extensive portfolio of state-of-the-art biomarkers and antibodies to help detect neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Its current pipeline encompasses, next to several phospho-tau specific antibodies for measurement in plasma, biomarkers targeting synaptic degeneration supporting prognosis of these devastating diseases.
Fujirebio is a trusted partner for high-quality IVD testing solutions and a historical pioneer in neurodegenerative disease diagnostics. The company will combine the unique know-how and biomarker portfolio of ADx NeuroSciences with both its own solid experience in bringing high quality IVD products to the market and its strategic CDMO partnerships that make unique testing solutions available to the entire diagnostics industry. The acquisition also concentrates considerable additional know-how, expertise, and resources in the Fujirebio Neuro Center of Excellence.
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., whose name represents “Healthcare for you” and which is a listed company on Tokyo Stock Exchange (TSE: 4544), is a global leader in the field of high-quality IVD testing. Founded in 1950, it has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. With Fujirebio Holdings Inc., located in Tokyo, Japan, its subsidiaries are located in Japan, US and Europe.
Fujirebio was the first company to develop and market CSF biomarkers for Alzheimer’s disease testing, under the Innogenetics brand, over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools.
About ADx NeuroSciences
ADx NeuroSciences is an R&D driven company specialized in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production, and worldwide commercialization of novel biomarkers.
ADx NeuroSciences was founded in 2011 and is now working with the top pharmaceutical and diagnostic companies in US, Europe, Japan, and China. These collaborations result in new diagnostic assays that support the development of promising drugs either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays are used in neurodegenerative diseases like Alzheimer’s disease and Parkinson’s and can be applied to a variety of platforms for research up to IVD use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005429/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
Banma Intelligence and Alipay Launch AI Cockpit Solution Powered by Alipay AI Pay, Enabling Seamless and Secure In-Car Transactions by Voice24.4.2026 16:04:00 CEST | Press release
At the 2026 Beijing International Automotive Exhibition (“Auto China 2026”), OS and AI technology company Banma Intelligence and Alipay today launched a new AI cockpit solution integrating Alipay AI Pay, enabling drivers to complete purchases by voice command directly from their vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424618328/en/ Industry-first AI Cockpit Solution with Alipay AI Pay Unveiled “In the past two years, smart cockpits have achieved rapid advances in perception and decision-making,” said Ming Cai, Banma Intelligence Chief Product Officer. “With large models onboard, vehicles can understand user intent and make recommendations. By integrating Alipay AI Pay into our AI cockpit solution, we are removing the last friction point in the in-car smart cockpit experience - drivers simply speak to pay, no phone required.” The new AI cockpit solution initially covers two high-frequency use cases: enterta
Spatial Announces the Release 2026 1.0.1: New Enhancements Across 3D InterOp, Data Prep, Meshing, and 3D Modeling SDKs24.4.2026 15:21:00 CEST | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced new enhancements across several of its product lines. These updates further strengthen Spatial’s commitment to delivering high-performance solutions that optimize interoperability, data preparation, and advanced modeling workflows. Designed to improve efficiency and robustness across CAD translation, modeling, meshing, and simulation processes, the latest updates introduce expanded format support, enhanced PMI handling, and new capabilities for complex geometry processing. 3D InterOp NX Reader Enhancement for 2D Drawings The NX reader imports 2D drawings as visualization data from NX 2412 and later versions. glTF Writer Supports Draco Compression glTF export incorporates Draco compression for meshes and point-clouds to significantly reduce output file sizes. Enhanced Support for Reading Product Manufacturing Information
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom